Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
111M
-
Number of holders
-
88
-
Total 13F shares, excl. options
-
36.6M
-
Shares change
-
+10.2M
-
Total reported value, excl. options
-
$1.03B
-
Value change
-
+$308M
-
Put/Call ratio
-
0.58
-
Number of buys
-
64
-
Number of sells
-
-31
-
Price
-
$28.15
Significant Holders of Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) as of Q3 2022
125 filings reported holding AMLX - Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share as of Q3 2022.
Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) has 88 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36.6M shares
of 111M outstanding shares and own 33.02% of the company stock.
Largest 10 shareholders include VIKING GLOBAL INVESTORS LP (5.77M shares), PERCEPTIVE ADVISORS LLC (5.47M shares), VANGUARD GROUP INC (3.51M shares), BlackRock Inc. (2.3M shares), BOXER CAPITAL, LLC (2.08M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.35M shares), FEDERATED HERMES, INC. (1.33M shares), Bain Capital Life Sciences Investors, LLC (1.02M shares), Woodline Partners LP (1.02M shares), and MILLENNIUM MANAGEMENT LLC (921K shares).
This table shows the top 88 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.